Thermo Fisher Scientific Inc. $TMO Shares Sold by Optas LLC

Optas LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,784 shares of the medical research company’s stock after selling 150 shares during the quarter. Optas LLC’s holdings in Thermo Fisher Scientific were worth $723,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in TMO. Nuveen LLC purchased a new stake in Thermo Fisher Scientific during the first quarter valued at about $532,360,000. EdgePoint Investment Group Inc. purchased a new stake in Thermo Fisher Scientific during the first quarter valued at about $172,139,000. Cohen Investment Advisors LLC grew its position in Thermo Fisher Scientific by 6,655.5% during the first quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company’s stock valued at $167,271,000 after acquiring an additional 331,180 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after acquiring an additional 329,974 shares during the period. Finally, Auto Owners Insurance Co grew its position in Thermo Fisher Scientific by 6,773.5% during the first quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock valued at $143,309,000 after acquiring an additional 283,810 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 0.5%

Shares of NYSE TMO opened at $536.21 on Thursday. The stock’s 50 day moving average price is $486.09 and its two-hundred day moving average price is $448.21. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The stock has a market capitalization of $202.48 billion, a P/E ratio of 31.01, a PEG ratio of 2.93 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the prior year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on TMO shares. Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price for the company in a research report on Friday, July 11th. HSBC reaffirmed a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. UBS Group upped their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. Finally, Evercore ISI upped their target price on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research report on Tuesday. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $590.60.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This represents a 0.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.